4 Healthcare Stock Stories for TGIF Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Vertex Pharmaceuticals (NASDAQ:VRTX): Closing price $45.44

Vertex said Friday that the Health Service Executive of Ireland will fund Kalydeco (ivacaftor), which represents the first medicine to treat the underlying cause of cystic fibrosis, for patients aged 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis is a rare genetic disease for which there is no cure, caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Ivacaftor helps the defective CFTR protein function more normally in persons with the G551D mutation.

vrtx

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business